ARCHIVES

Phase III Afatinib Trial Met Primary Endpoint In Stage IIIb or IV Cancer with EGFR Mutation

This article is from The Cancer Letter archive.

Vol. 35 No. 6 | June 29, 2012

Download PDF Visit The Full Archive

Related Articles

In Brief: ACS to support $2 Billion NCI Budget; NCAB Backs Minority Enhancement Core Supplements

February 19, 1988

Highlights of NCDDGs: 3 Drugs on Market, 12 in Development; Advisors Approve Plan to Issue $10.5 Million Contract For Pediatric Preclinical Testing Program

November 29, 2002

In Brief: ACS to Spend Record $85 Million On Research: AACR To Honor Hanafusa, DeVita, Barbacid

March 14, 1986

IOM Calls For Rapid Reform Of Health Case System.

March 9, 2001

In Brief: Increased Output Can Hold Down High Let Cost, Kligerman says; No More Groups On The Block

March 18, 1977

Jerome Yates Named VP For Research At ACS

February 8, 2002